Investing in CRISPR Therapeutics AG (CRSP)  ➔  Intrinsic value

Prev. close$100.84 
Previous Close$100.84  
Valuation MethodValuePotential 
Chepakovich Model$20.29-80%recalculate
Graham Formula$0.00-100%recalculate

Latest news

11 May

Cathie Wood’s ARK Wasn’t Built for a Flood => The Wall Street Journal 12:12PM

Avoid the Dogecoin Crash by Buying These 2 Growth Stocks Instead => Motley Fool 6:40AM

7 May

Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer => Benzinga 11:38AM

With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger Market => Motley Fool 6:40AM

6 May

CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer => GlobeNewswire 4:01PM

4 May

This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here Soon => Motley Fool 6:00AM

1 May

Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock? => Motley Fool 6:10AM

29 Apr

Vertex Pharmaceuticals Inc (VRTX) Q1 2021 Earnings Call Transcript => Motley Fool 10:01PM

Best Biotech Stocks & ETFs for mRNA, Gene Editing => Zacks 4:17PM

CRISPR Therapeutics to Participate in Upcoming Investor Conferences => GlobeNewswire 8:30AM

Shareholders Are Thrilled That The CRISPR Therapeutics (NASDAQ:CRSP) Share Price Increased 179% => Simply Wall St. 3:26AM

28 Apr

CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting => GlobeNewswire 4:01PM

Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News => Zacks 12:18PM

CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/Y => Zacks 9:56AM

27 Apr

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates => Zacks 5:15PM

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results => GlobeNewswire 4:01PM

Crispr Therapeutics Gets Relative Strength Rating Upgrade => Investor's Business Daily 1:53PM

26 Apr

Skyworks Lifts Nasdaq Ahead of Earnings; CRISPR Keeps Moving Forward => Motley Fool 2:47PM

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia => GlobeNewswire 8:30AM

23 Apr

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know => Zacks 5:50PM

Is a Beat in Store for CRISPR (CRSP) This Earnings Season? => Zacks 8:09AM

2 Unstoppable Cathie Wood Stocks That Could Make You Rich => Motley Fool 6:35AM

21 Apr

Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates => Zacks 2:54PM

Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership => Zacks 8:55AM

CRISPR Therapeutics Is Upgraded After $900 Million Deal => 8:10AM

20 Apr

Vertex Pharmaceuticals Raises Bet on CRISPR Therapeutics => Motley Fool 4:29PM

Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for => Zacks 12:31PM

Vertex Is Buying Majority Rights to Gene-Editing Therapy From CRISPR Therapeutics => 10:20AM

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia => GlobeNewswire 7:15AM

16 Apr

CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today => InvestorPlace 3:51PM

10 Apr

CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function => GlobeNewswire 8:31AM

6 Apr

Is CRSP Stock A Buy or Sell? => Insider Monkey 2:00PM

CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference => GlobeNewswire 8:00AM

2 Apr

Here's the Holy Grail of Gene Editing => Motley Fool 8:06AM

1 Apr

Crispr Therapeutics Stock Sees Improved Relative Strength Rating => Investor's Business Daily 2:11PM

25 Mar

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know => Zacks 5:50PM

23 Mar

CRISPR Therapeutics Could Suffer Further Steep Losses => 11:00AM

21 Mar

2 Cathie Wood Stocks That Are 40% Off => Motley Fool 6:43AM

18 Mar

Roblox Goes Public, and the Future of CRISPR and Gene Editing => Motley Fool 6:26PM

CRISPR Therapeutics AG (CRSP) Down 12.6% Since Last Earnings Report: Can It Rebound? => Zacks 11:30AM

Company description

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.